Trials / Completed
CompletedNCT06363630
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
A Phase 1, Open-label, 2-part, 2-period, Fixed-sequence, Crossover Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of Golcadomide (BMS-986369) in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itraconazole | Specified dose on specified days. |
| DRUG | Rifampin | Specified dose on specified days |
| DRUG | Golcadomide | Specified dose on specified days |
Timeline
- Start date
- 2024-04-23
- Primary completion
- 2024-08-29
- Completion
- 2024-08-29
- First posted
- 2024-04-12
- Last updated
- 2024-09-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06363630. Inclusion in this directory is not an endorsement.